Oluwole, Olalekan O. http://orcid.org/0000-0001-8525-9641
Forcade, Edouard http://orcid.org/0000-0002-8873-2868
Muñoz, Javier
de Guibert, Sophie
Vose, Julie M. http://orcid.org/0000-0003-1015-7434
Bartlett, Nancy L.
Lin, Yi http://orcid.org/0000-0002-1556-6416
Deol, Abhinav http://orcid.org/0000-0003-0947-8871
McSweeney, Peter
Goy, Andre H.
Kersten, Marie José
Jacobson, Caron A.
Farooq, Umar
Minnema, Monique C. http://orcid.org/0000-0002-3139-8379
Thieblemont, Catherine http://orcid.org/0000-0002-9941-2448
Timmerman, John M.
Stiff, Patrick http://orcid.org/0000-0001-8265-9340
Avivi, Irit
Tzachanis, Dimitrios
Zheng, Yan
Vardhanabhuti, Saran
Nater, Jenny http://orcid.org/0000-0001-9495-0653
Shen, Rhine R.
Miao, Harry
Kim, Jenny J.
van Meerten, Tom
Funding for this research was provided by:
This study was funded by Kite, a Gilead Company
Article History
Received: 18 August 2023
Revised: 28 November 2023
Accepted: 29 November 2023
First Online: 4 January 2024
Competing interests
: OOO<b>:</b> honoraria from Kite, a Gilead Company, Pfizer, and Gilead; consulting/advisory role for Pfizer, Kite, a Gilead Company, Gilead, AbbVie, Janssen, TG Therapeutics, ADC Therapeutics, Novartis, Epizyme, Curio Science, Nektar Therapeutics, Cargo Therapeutics, and Caribou Biosciences; institutional funding from Kite, a Gilead Company, Pfizer, Daiichi Sankyo, and Allogene. EF: speakers’ bureau participation for Gilead, Jazz, Novartis, and GSK; and travel support from Gilead, Jazz, Sanofi, and MSD. JM: honoraria from Curio, Kyowa Kirin, OncView, Physicians’ Education Resource, Seagen, and Targeted Oncology; consulting/advisory role for ADC Therapeutics, Alexion, Bayer, BeiGene, Bristol Myers Squibb, Debiopharm, Epizyme, Fosun Kite, Genmab, Innovent, Janssen, Juno/Celgene, Karyopharm, Kite, a Gilead Company, Kyowa Kirin, MorphoSys/Incyte, Novartis, Pfizer, Pharmacyclics/AbbVie, Seagen, and Servier; speakers’ bureau participation for Acrotech/Aurobindo, AstraZeneca, Bayer, BeiGene, Celgene/Bristol Myers Squibb, Genentech/Roche, Kite, a Gilead Company, Kyowa, Pharmacyclics/Janssen, Seagen, and Verastem; and research funding (paid to institution) from Bayer, Celgene, Genentech, Gilead/Kite, Incyte, Janssen, Merck, Millennium, Pharmacyclics, Portola, and Seagen. SdG: honoraria from and consultancy or advisory role for Gilead, AbbVie, and Janssen. JMV: honoraria from AstraZeneca, Janssen, Lilly, and AbbVie; consulting or advisory role for Johnson and Johnson, Daiichi Sankyo, Pharmacyclics, and MorphoSys; and research funding from Kite, a Gilead Company. NLB: consultancy or advisory role for ADC Therapeutics, Roche/Genentech, and Seagen; and research funding from ADC Therapeutics, Autolus, Bristol Myers Squibb, Celgene, Forty Seven, Genentech, Janssen, Kite, a Gilead Company, Merck, Millennium, Pharmacyclics, and Seagen. YL: consultancy or advisory role for bluebird bio, Celgene, Gamida Cell, Janssen, Novartis, Juno, Kite, a Gilead Company, Legend, Sorrento, and Vineti; research funding from bluebird bio, Celgene, Janssen, Kite, a Gilead Company, Merck, and Takeda. AD: consultancy or advisory role for Adicet, Janssen, and Kite, a Gilead Company. PMS: honoraria from, consulting or advisory role for, and speakers’ bureau participation for Kite, a Gilead Company, and research funding from AlloVir, Autolus, Kite, a Gilead Company, and Novartis. AHG: employment with Regional Cancer Care Associates, OMI; leadership role and stock or other ownership at COTA (Cancer Outcome Tracking Analysis) and Genomic Testing Cooperative, Resilience; honoraria from AstraZeneca, Bristol Myers Squibb, Celgene, Elsevier PracticeUpdate: Oncology, Incyte, Janssen, Kite, a Gilead Company, MorphoSys, Novartis, OncLive Peer Exchange, Pharmacyclics, Vincerx, and Xcenda; consultancy or advisory role for AbbVie, Bristol Myers Squibb, Celgene, Elsevier PracticeUpdate: Oncology, Janssen, Kite, a Gilead Company, Medscape, Michael J. Hennessy Associates, Inc., Novartis, Pharmacyclics, and Physicians’ Education Resource; research funding from Acerta, AstraZeneca, Celgene, Genentech, Hoffmann-La Roche, Infinity Pharmaceuticals, Janssen, Karyopharm, and Pharmacyclics; and other relationships with MorphoSys and Incyte Steering Committee, AstraZeneca MCL Steering Committee, Vincerx Scientific Advisory Board. MJK: honoraria from and consultancy or advisory role for BMS/Celgene, Kite, a Gilead Company, Miltenyi Biotec, Novartis, Adicet Bio and Roche; research funding from Kite, a Gilead Company, Roche, Takeda, and Celgene; and travel support from Kite, a Gilead Company, Miltenyi Biotec, Novartis, and Roche. CAJ: honoraria from Kite, a Gilead Company, Novartis, BMS/Celgene, Instil Bio, ImmPACT Bio, Lonza, Ipsen, Epizyme, bluebird bio, and Daiichi Sankyo; consulting or advisory role for Kite, a Gilead Company, Novartis, BMS/Celgene, Instil Bio, ImmPACT Bio, Lonza, Ipsen, Epizyme, bluebird bio, and Daiichi Sankyo; and research funding from Kite, a Gilead Company, and Pfizer. UF: honoraria from Caribou and Kite, a Gilead Company, and consulting or advisory role for MorphoSys. MCM: consultancy or advisory role for Gilead, Bristol Myers Squibb, GSK, CDR-life, and Janssen-Cilag; speakers’ bureau participation for WebMD; and research support from BeiGene. CT: honoraria from BMS, Roche AbbVie, Novartis, Kite, a Gilead Company, Incyte, Amgen, and Takeda; consulting or advisory role for BMS, Roche, AbbVie, Novartis, Kite, a Gilead Company, Incyte, Amgen, and Takeda; and research funding from Gilead and Novartis. JMT: consultancy or advisory role for Kite, a Gilead Company; and research funding from Bristol Myers Squibb, Kite, a Gilead Company, Merck, and Spectrum. PS: honoraria from and consultancy or advisory role for MorphoSys and CRISPR Therapeutics; and research funding from Amgen, Pfizer, Karyopharm, Gilead, Incyte, Gamida Cell, Seagen, and Cellectar. IA: speakers’ bureau participation for Kite, a Gilead Company, and Novartis. DT: consultancy or advisory role for BMS, EUSA, Partner, and Takeda, and research funding from BMS. JJK, YZ, JN, HM: employment with Kite, a Gilead Company; and stock or other ownership in Gilead Sciences. RRS: employment with, leadership role with, stock or other ownership in, and patents, royalties, and other intellectual property from Atara and Kite, a Gilead Company. SV: employment with, research funding from Kite, a Gilead Company; and stock or other ownership in Gilead Sciences. TvM: honoraria from Kite, a Gilead Company; consultancy or advisory role for Janssen and Kite, a Gilead Company; and research funding from Celgene/BMS and Genentech.